Catalase (CAT) and other novel antioxidants, such as glucagon-like peptide-1 (GLP-1) and exendin-4 (EXE-4; a natural GLP-1 analog) are used as cytoprotective agents for the prevention and treatment of diabetic retinopathy [6,7]. This evidence concerns the gene GLP1R and diabetic retinopathy.